EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Posted: Thu Sep 21, 2006 3:27 am Post subject: Oral Cladribine
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Serono announced today that oral cladribine has been designated a Fast Track product by the US Food and Drug Administration (FDA). This designation covers patients with relapsing forms of multiple sclerosis.
Serono's proprietary oral formulation of cladribine for the treatment of multiple sclerosis is currently being evaluated in a multi-center, multi-national Phase III study, CLARITY (CLAdRIbine Tablets Treating MS OrallY) . It is a two-year, double-blind, placebo-controlled study involving over 1,200 patients. Patient enrollment into this pivotal trial is planned to be completed by the end of 2006.
"We are very pleased that oral cladribine has been designated a Fast Track product," said Ernesto Bertarelli, CEO of Serono. "As a leader in multiple sclerosis, we are committed to providing new treatment options that can further improve the quality of the lives of people with this serious disease and our objective is to bring to them the first oral disease modifying treatment."
"Thanks to decades of research, there are injectible drugs available to treat some forms of MS, but there is certainly a need for more and even better therapies to treat all forms of the disease. Having an effective oral therapy for MS would be a major step forward in improving quality of life for people with MS," said Dr. John Richert, Vice President, Research and Clinical Programs, at the National Multiple Sclerosis Society.
Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Under Fast Track designation oral cladribine is eligible for Priority Review and FDA may consider for review portions of the marketing application before the New Drug Application (NDA) is completed.
About cladribine
Cladribine is a purine nucleoside analogue that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are involved in the pathological process of multiple sclerosis. Through its differentiated mechanism of action, oral cladribine may offer an alternative option to patients with multiple sclerosis.
Could this be the real reason for the FDA fast-track? "While data do not support its use as a first-line MS treatment, cladribine may be a promising agent for refractory patients with secondary progressive MS."
Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis
Ann Pharmacother. 2006 Sep 19
Brousil JA, Roberts RJ, Schlein AL.
St. Louis College of Pharmacy, St. Louis, MO.
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of cladribine, a purine analog undergoing Phase III trials for approval of its use in the treatment of multiple sclerosis (MS).
DATA SOURCES: A MEDLINE search (1966-September 2006) was conducted using the key words cladribine and multiple sclerosis. No limits were placed on the search.
STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to cladribine and MS were reviewed. The trials examining the role of cladribine in MS were analyzed.
DATA SYNTHESIS: Cladribine is a purine analog that demonstrates lymphocytotoxic activity. Recent data suggest that cladribine may have a role in the treatment of relapsing-remitting and the progressive forms of MS. In these studies, cladribine has shown mixed results in decreasing neurologic disability, as measured by various rating scales, but has consistently shown positive results in reducing the number of enhancing lesions, which reflects a measure of disease activity. To date, there is one ongoing study examining the role of oral cladribine in the treatment of relapsing-remitting MS. The incidence of adverse effects with cladribine has been significantly greater than with placebo, with the most common being myelosuppression.
CONCLUSIONS: While data do not support its use as a first-line MS treatment, cladribine may be a promising agent for refractory patients with secondary progressive MS. Further studies are warranted.
I'm not sure what 'fast-tracking' means given that the Phase 3 trials have not completed enrolling. I can't see Phase III results out until end of 2008, so not sure why the FDA are making announcements at this stage.
I keep seeing the term 'refractory patients' and 'refractory MS' but haven't got a clue what refractory means.
Posted: Thu Sep 21, 2006 11:36 am Post subject: Cladribine
It has been shown for years that lesions do not correlate well with impairment. The fact that the trial results do not show decreased neurological disability makes this pill pretty useless, in my opinion.
In these studies, "cladribine has shown mixed results in decreasing neurologic disability, as measured by various rating scales, but has consistently shown positive results in reducing the number of enhancing lesions, which reflects a measure of disease activity. "
Bromley, I just reread your initial post and it specifically says fast-tracked for relapsing remitting patients, so I guess my Pubmed abstract is unrelated.
I'm with you about refractory, I would have thought refractory would refer to a period between events where the body takes time to recover, but it doesn't appear to be the context in which they're using the term.
I've e-mailed one of my neuros who is overseeing a Cladribine study to ask him whether this treatment offers much more over the current DMDs apart from being in tablet form.
GWA,
You read my mind and I was a few seconds from posting exactly the same. Isn't it time these drugs companies ask the customer what they want? They seem to meet the needs of the researchers eg fewer lesions, fewer relapses, but as the end user, we want no disability, reversal of disability etc etc. It's the academic researchers who are running the show not the sufferers.
Joined: Oct 10, 2005 Posts: 410 Location: Missouri, USA
Posted: Thu Sep 21, 2006 2:30 pm Post subject:
The only time I would fast track an MS drug is if I saw tangible, physical, clinical improvement in MS patients(PLURAL, meaning more than one). That justifies a fast track. How stupid to fast track something that hasn't been studied and who knows what if any benefit oral cladribine has. It sounds like marketing HYPE to me. BS
Joined: Oct 10, 2005 Posts: 410 Location: Missouri, USA
Posted: Fri Sep 22, 2006 7:52 am Post subject:
Maybe all of us here at Thisisms.com could get rich? Here is an idea...
Lets create a special pill. We can call it Sucavax, that sounds effective right? The ingredients will be SUGAR. We will have everyone at thisisms.com be in the clinical trial. We will see its safety profile through each of the stages. Remember, we will only use data that makes sucavax look like it has a "beneficial effect". If nothing else, we can rest on the laurels of the placebo effect, why not? The CRAB's do. We could do studies on mice, make them injest this sucavax, and record data from only the mice whos EAE took a less severe disease progression.
BINGO!!! You have a another drug!!! Then it would be CRABS, and we would all be rich like Serono, Glaxo, Biogen Idec, just to name a few.
Joined: Oct 10, 2005 Posts: 410 Location: Missouri, USA
Posted: Fri Sep 22, 2006 7:53 am Post subject:
I forgot to mention that once the safety profile was determined (and this is crucial), we would apply for FDA fastracking... It won't sell as good if we don't.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
